Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 18/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.40 |
| ▸ | SLC2A9 | Q9NRM0 | 2/20 | 0.33 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362515 | 1.00 | SLC22A12 (0.40) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL17069753 | 0.83 | SLC22A12 (0.41) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL3418015 | 0.83 | SLC22A12 (0.47) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL21182092 | 0.83 | — | — | |
| SCHEMBL23022609 | 0.80 | SLC22A12 (0.43) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL20923678 | 0.77 | HTT (0.33) | SLC22A12 | |
| SCHEMBL19867741 | 0.76 | — | — | |
| SCHEMBL27951684 | 0.76 | SLC22A12 (0.43) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL28040527 | 0.76 | HTR6 (0.41) | SLC22A12 | |
| SCHEMBL19867947 | 0.75 | SLC22A12 (0.41) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365180-B2 | Resolution method for axis chiral enantiomers of lesinurad | CHINA RESOURCES SAIKE PHARMACEUTICAL CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| CN-110878057-B | Method for preparing Raxinader | 江苏宇田医药有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-113979958-A | Preparation method of Raschindde related impurities | 海南鑫开源医药科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-111153862-B | Raisinard refining method | 北京鑫开元医药科技有限公司海南分公司 | 2021-07-06 | — | — | CN | disclosed |
| CN-112778223-A | Preparation method of Raschindde oxidation impurities | 海南鑫开源医药科技有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-111116501-B | Synthesis method of Ravinard intermediate capable of effectively reducing impurity content | 北京鑫开元医药科技有限公司海南分公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20210053928-A1 | RESOLUTION METHOD FOR AXIS CHIRAL ENANTIOMERS OF LESINURAD | CHINA RESOURCES SAIKE PHARMACEUTICAL CO., LTD (CN) | 2021-02-25 | — | — | US | disclosed |
| CN-110467580-B | Resolution method of Raxinard axis chiral enantiomer | 华润赛科药业有限责任公司 | 2020-11-13 | — | — | CN | disclosed |
| EP-3279188-B1 | AXIALLY CHIRAL ISOMERS, AND PREPARATION METHODS THEREFOR AND PHARMACEUTICAL USES THEREOF | MEDSHINE DISCOVERY INC (CN) | 2020-09-09 | — | — | EP | disclosed |
| CN-111153862-A | Raisinard refining method | 北京鑫开元医药科技有限公司海南分公司 | 2020-05-15 | — | — | CN | disclosed |
| CN-105263913-A | Thio-1,2,4-triazole derivatives and method for preparing the same | SUNSHINE LAKE PHARMA CO LTD | 2016-01-20 | — | — | CN | disclosed |
| US-20150252010-A1 | MANUFACTURE OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | ARDEA BIOSCIENCES, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150252010-A1 | MANUFACTURE OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | ARDEA BIOSCIENCES, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150252010-A1 | MANUFACTURE OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | ARDEA BIOSCIENCES, INC. | 2015-09-10 | — | — | US | disclosed |
| EP-2870142-A1 | MANUFACTURE OF 2- (5- BROMO-4- (4-CYCLOPROPYLNAPHTHALEN-1-YL) -4H-1,2,4-TRIAZOL-3-YLTHIO) ACETIC ACID | Ardea Biosciences, Inc. (US) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014198241-A1 | THIO-1,2,4-TRIAZOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014198241-A1 | THIO-1,2,4-TRIAZOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014008295-A1 | MANUFACTURE OF 2- (5- BROMO-4 (-CYCLOPROPYLNAPHTHALEN-1-YL) -4H-1,2,4-TRIAZOL-3-YLTHIO) ACETIC ACID | ARDEA BIOSCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014008295-A1 | MANUFACTURE OF 2- (5- BROMO-4 (-CYCLOPROPYLNAPHTHALEN-1-YL) -4H-1,2,4-TRIAZOL-3-YLTHIO) ACETIC ACID | ARDEA BIOSCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2007050087-A1 | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252010-A1 | MANUFACTURE OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | CYP1B1, ABAT, ALDH18A1 | SLC22A12 3336/4885CYP2C9 51/4885CYP2C19 72/4885 |
| US-20210053928-A1 | RESOLUTION METHOD FOR AXIS CHIRAL ENANTIOMERS OF LESINURAD | CLK4, CLK1, CLK3 | SLC22A12 4629/4885CYP2C9 1592/4885CYP2C19 2093/4885 |
| US-11365180-B2 | Resolution method for axis chiral enantiomers of lesinurad | CLK4, CLK1, CLK3 | SLC22A12 4629/4885CYP2C9 1592/4885CYP2C19 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.